CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...
Phase 3
Sevilla, Spain and 107 other locations
levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
Phase 2
Sevilla, Spain and 136 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Sevilla, Spain and 179 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 3
Sevilla, Spain and 59 other locations
as:* Monotherapy, or* Combination therapy for relapsed/refractory chronic lymphocytic leukemia (R/R CLL): * epcoritamab +...
Phase 1, Phase 2
Sevilla, Spain and 76 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Sevilla, Spain and 86 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have...
Phase 3
Sevilla, Spain and 231 other locations
This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or...
Phase 3
Sevilla, Spain and 41 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Sevilla, Spain and 216 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with...
Phase 1
Sevilla, Spain and 40 other locations
Clinical trials
Research sites
Resources
Legal